Bionic technologies transforming the science of healthcare delivery.
作者信息
Waldman Scott A, Terzic Andre
机构信息
Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
出版信息
Clin Transl Sci. 2011 Apr;4(2):84-6. doi: 10.1111/j.1752-8062.2011.00271.x.
Abstract
摘要
相似文献
1
Bionic technologies transforming the science of healthcare delivery.仿生技术正在改变医疗保健服务科学。
Clin Transl Sci. 2011 Apr;4(2):84-6. doi: 10.1111/j.1752-8062.2011.00271.x.
2
A role for entrepreneurs: an observation on lowering healthcare costs via technology innovation.企业家的作用：关于通过技术创新降低医疗成本的观察
Am J Prev Med. 2013 Jan;44(1 Suppl 1):S43-7. doi: 10.1016/j.amepre.2012.09.006.
3
[Health system, discuss the prospects: dialoguing ].[卫生系统，探讨前景：对话]
Rev Med Suisse. 2013 Mar 6;9(376):526-8.
4
Lowering the cost of health care: the West Health initiative.降低医疗保健成本：西部健康倡议
Am J Prev Med. 2013 Jan;44(1 Suppl 1):S51-3. doi: 10.1016/j.amepre.2012.09.012.
5
Putting advanced materials to work for healthcare.让先进材料为医疗保健服务。
Adv Mater. 2011 Mar 25;23(12):H8-9. doi: 10.1002/adma.201100814.
6
Improving healthcare through advances in point-of-care technologies.
Clin Chem Lab Med. 2008;46(1):1-2. doi: 10.1515/CCLM.2008.028.
7
Healthcare venture capital for Africa.非洲的医疗保健风险投资。
Science. 2011 Feb 4;331(6017):532-3; author reply 533-4. doi: 10.1126/science.331.6017.532-b.
8
Heartfile: using technology to get healthcare funding to poor patients in Pakistan.心脏档案：利用技术为巴基斯坦贫困患者获取医疗资金。
BMJ. 2012 Aug 7;345:e5156. doi: 10.1136/bmj.e5156.
9
Rotten context: the unaffordability of technological advances.糟糕的背景：技术进步带来的难以承受之重。
Med Health Care Philos. 2015 Nov;18(4):459-61. doi: 10.1007/s11019-015-9664-3.
10
Is there an alternative to quality-adjusted life years for supporting healthcare decision making?在支持医疗保健决策方面，是否存在质量调整生命年的替代方法？
Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):351-7. doi: 10.1080/14737167.2016.1184975.
引用本文的文献
1
The medical cyborg concept.医学半机械人概念。
EMBnet J. 2022 Apr;27. doi: 10.14806/ej.27.0.1005. Epub 2022 Apr 21.
本文引用的文献
1
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.预测美国心血管疾病的未来：美国心脏协会的政策声明。
Circulation. 2011 Mar 1;123(8):933-44. doi: 10.1161/CIR.0b013e31820a55f5. Epub 2011 Jan 24.
2
Clinical and translational science: from bench-bedside to global village.临床与转化科学：从实验室到床边再到地球村。
Clin Transl Sci. 2010 Oct;3(5):254-7. doi: 10.1111/j.1752-8062.2010.00227.x.
3
The pathway to the closed-loop artificial pancreas: research and commercial perspectives.闭环人工胰腺之路：研究与商业视角
Pediatr Endocrinol Rev. 2010 Aug;7 Suppl 3:445-51.
4
Molecular therapy drives patient-centric health care paradigms.分子疗法推动以患者为中心的医疗保健模式。
Clin Transl Sci. 2010 Aug;3(4):170-1. doi: 10.1111/j.1752-8062.2010.00203.x.
5
Molecular therapeutics from knowledge to delivery.从知识到递送的分子疗法。
Clin Pharmacol Ther. 2010 Jun;87(6):619-23. doi: 10.1038/clpt.2010.61.
6
Targeted diagnostics and therapeutics for individualized patient management.用于个体化患者管理的靶向诊断与治疗
Biomark Med. 2007 Jun;1(1):3-8. doi: 10.2217/17520363.1.1.3.
7
Experimental therapeutics: a paradigm for personalized medicine.实验性治疗学：个性化医疗的范例
Clin Transl Sci. 2009 Dec;2(6):436-8. doi: 10.1111/j.1752-8062.2009.00146.x.
8
Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy.分子诊断。处于个性化医疗、医疗保健服务及公共政策的交叉点。
Clin Transl Sci. 2009 Feb;2(1):6-8. doi: 10.1111/j.1752-8062.2008.00067.x.
9
Clinically available pharmacogenomics tests.临床可用的药物基因组学检测。
Clin Pharmacol Ther. 2009 Jul;86(1):109-13. doi: 10.1038/clpt.2009.39. Epub 2009 Apr 15.
10
Implantable cardioverter-defibrillators after myocardial infarction.心肌梗死后的植入式心脏复律除颤器
N Engl J Med. 2008 Nov 20;359(21):2245-53. doi: 10.1056/NEJMra0803409.
Zotero 插件